logo
Smaller SBA Loans Mean Bigger Benefits For SMB Ecosystem

Smaller SBA Loans Mean Bigger Benefits For SMB Ecosystem

Forbes8 hours ago
Having an idea is easy; executing the vision is the hard part, according to Guy Kawasaki. As one of the original employees responsible for marketing Apple's first Macintosh computer in the 1980s, he should know.
However, executing a vision requires access to capital, and America's small businesses, particularly those qualified under the SBA, are facing a significant shortage of funds.
Earlier this summer, I had the opportunity, alongside other lenders, to meet with senior executives at the Small Business Administration in Washington. Together, we presented a three-pronged strategy aimed at increasing small-dollar SBA loans of $150,000 or less. Our goal is to make them more affordable for lenders, more attractive for SMBs, and more profitable for the SBA. Here's what we shared with them.
SBA-Qualified Borrowers are Essential for the Health of the Lending Community
Running a business that is designed for long-term success and capable of pursuing its vision requires timely access to the right capital. Financial institutions play a crucial role in the success of SMBs. Among lenders, the most respected SMBs are those that qualify for SBA loans due to their creditworthiness and strategic use of capital.
Maintaining a strong relationship between SBA-qualified borrowers, loyal and creditworthy consumers, and lenders is vital. According to data from Lendio's latest whitepaper, 'Modernizing the Lending Experience for SBA-qualified Borrowers', SBA-qualified borrowers are more loyal to their banks or credit unions than the general population of borrowers. However, they're open to seek alternative lenders if they feel their needs are not adequately met, customer service is lacking, and they can find a better digital banking experience elsewhere.
Approximately ten years ago, the SBA introduced the SBSS (Small Business Scoring Service) to assign a numerical scoring value to individual borrowers based on their creditworthiness and perceived ability to repay a loan in full. While helpful in theory, lenders often become complacent with a metric that has proven inaccurate over time, leading to loans that underperform and have severe repercussions for both lenders and borrowers.
Analyzing cash flow data effectively addresses this issue. This information is vital because it is unalterable, allowing lenders to accurately evaluate an SMB's cash flow and overall financial health. Platforms like Lendio's Intelligent Lending offer banks and financial institutions access to this valuable data, providing deeper insights and resulting in a 45% reduction in manual underwriting costs for lenders who utilize cash flow analysis. In addition to making these loans more profitable, it is also essential to minimize the human resources required for the underwriting process, so that a greater number of smaller-dollar loans can reach borrowers.
Our data indicate that approximately 85% of small businesses in America are seeking a loan of less than $150,000; however, underwriting such small-dollar loans is not beneficial for lenders.
When they do, they often apply the same underwriting standards to a million-dollar loan as they would to a $100,000 loan, resulting in a prime interest rate of 4-6% over a ten-year term or 20-24% at a five-year term. The process is too time-intensive and costly, with not enough ROI for lenders to continue pursuing and untenable lending terms for SMBs to accept.
Risk-adjusted pricing, where the terms are dependent on the borrower's risk profile, could make these loans easier to underwrite, more profitable, and better performing for lenders, thereby addressing this issue.
The new Small Business Administration, just six months into its term, faces a challenging task: addressing what it believes is a failing portfolio. Given the data available, it's not surprising that they are convinced that larger dollar loans are the key solution.
They have also begun implementing significant policy changes, including stricter ownership requirements, staff reductions, and office restructuring.
Like many new administrations, they are eager to demonstrate their value to Americans and correct the perceived mistakes of their predecessors. However, they should avoid drastic measures that could undermine existing systems. Our goal of supporting SMBs and lenders must also include ensuring the SBA's success. The SBA is a vital partner in the quest for access to capital, and building strong working relationships is essential. So, what does this mean for the future of lending?
SBA-qualified borrowers are at the forefront of SMB lending, and any shifts in their expectations will significantly impact the market. Both lenders and the SBA should pay attention to these trends to maintain this crucial relationship and make improvements to small-dollar loans a top priority.
The lending community believes change is possible. Our next steps will involve surveying lenders who currently provide small-dollar loans and hosting a summit to discuss best practices and offer recommendations to the SBA.
To increase small-dollar loans to SMBs, strong partnerships, open lines of communication, and a greater reliance on effective analytics will be critical.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Masimo sues US Customs over approval of Apple Watch imports
Masimo sues US Customs over approval of Apple Watch imports

Yahoo

time18 minutes ago

  • Yahoo

Masimo sues US Customs over approval of Apple Watch imports

By Blake Brittain WASHINGTON (Reuters) -Medical monitoring technology company Masimo sued U.S. Customs and Border Protection on Wednesday over a decision by the agency that allowed Apple to import Apple Watches with blood-oxygen reading technology during a patent dispute between the companies. Masimo said in the lawsuit in Washington, D.C., federal court that Customs improperly determined that Apple can import watches with pulse oximetry technology, reversing its own decision from last year without notifying Masimo. Masimo told the court that it learned of the agency's August 1 decision only after Apple announced it would reintroduce blood-oxygen reading to its watches last week. Spokespeople for Apple and Customs did not immediately respond to requests for comment. A Masimo spokesperson declined to comment. Irvine, California-based Masimo has accused Apple of hiring away its employees and stealing its pulse oximetry technology to use in its Apple Watches. Masimo has separately sued Apple for patent infringement and trade secret theft in ongoing federal court cases. Masimo convinced the U.S. International Trade Commission to block imports of Apple's Series 9 and Ultra 2 smartwatches in 2023 based on a determination that Apple's technology for reading blood oxygen levels infringed Masimo's patents. Apple has continued to sell Customs-approved redesigned watches without pulse oximetry since the ITC's decision. Apple said on Aug. 14 that it would reintroduce its smartwatches' blood-oxygen reading capabilities with approval from Customs. Masimo said the agency's decision to approve the watches without input from Masimo or any "meaningful justification" deprived the company of its rights. "CBP's function is to enforce ITC exclusion orders, not to create loopholes that render them ineffective," Masimo said. Masimo asked the Washington court to halt the agency's ruling and continue to block Apple from selling watches with the blood-oxygen feature. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Why Medtronic Stock Raced Higher Today
Why Medtronic Stock Raced Higher Today

Yahoo

time18 minutes ago

  • Yahoo

Why Medtronic Stock Raced Higher Today

Key Points Investors traded out of the company the previous day following its latest earnings release. The stock came roaring back on Hump Day, however. 10 stocks we like better than Medtronic › A clutch of post-earnings price target increases by analysts helped raise Medtronic's (NYSE: MDT) stock at a healthy rate on Wednesday. The sturdy medical device specialist's shares rose by almost 4% on the day as a consequence, a rate that looked especially good next to the S&P 500's (SNPINDEX: ^GSPC) 0.2% drop. Healthy raises Following a trend that began Tuesday after Medtronic published its first quarter of fiscal 2026 figures. The company posted revenue growth of 8% (to almost $8.6 billion), and improved non-GAAP (generally accepted accounting principles) adjusted net income by 2% to slightly over $1.6 billion. Both headline numbers beat the consensus analyst estimates, albeit not by much. The market, which collectively loves a crushing beat on analyst estimates, basically shrugged at this. Many investors traded out of Medtronic that day. The sun was shining brighter on Wednesday thanks to that series of price target bumps. By my count, seven analysts tracking the stock upped their fair-value assessments. Among these were pundits at such financial industry heavyweights as Wells Fargo, J.P. Morgan, and international bank UBS. Positive moves from cautious pundits I should note that in all cases, those price target raises were incremental. Nevertheless, the raising analysts frequently sounded bullish notes on Medtronic's prospects. One example was Leerink Partners' Mike Kratky, who only added $1 per share for a new level of $111, but maintained his outperform (read: buy) recommendation. According to reports, Kratky praised several elements of the company's operations, particularly its cardiac ablation solutions unit. Less positively, the analyst wrote that Medtronic suffered from weakness in its domestic sales. Should you invest $1,000 in Medtronic right now? Before you buy stock in Medtronic, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Medtronic wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $654,781!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,076,588!* Now, it's worth noting Stock Advisor's total average return is 1,055% — a market-crushing outperformance compared to 183% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of August 18, 2025 Wells Fargo is an advertising partner of Motley Fool Money. Eric Volkman has no position in any of the stocks mentioned. The Motley Fool recommends Medtronic and recommends the following options: long January 2026 $75 calls on Medtronic and short January 2026 $85 calls on Medtronic. The Motley Fool has a disclosure policy. Why Medtronic Stock Raced Higher Today was originally published by The Motley Fool Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store